This inventor holds 1 USPTO granted patent. Top assignee: E.i. Dupont De Nemours and Company. Active years: 1993.
Company Filing History:
Years Active: 1993
Title: The Innovative Journey of Inventor Lisa C. Grimminger
Introduction
Lisa C. Grimminger is a prominent inventor based in Oxford, PA, who has made significant contributions to the field of biocompatible materials. With a focus on enhancing the compatibility of polyurethane surfaces, her groundbreaking work holds promise for advancing medical applications, particularly in vascular grafts and artificial heart components.
Latest Patents
Grimminger is credited with one notable patent titled "Biocompatible Polyurethanes by Treatment with Polyoxazoline Block." This innovation reveals a method to improve the biocompatibility of polyurethane surfaces, particularly in contact with blood. By employing a block copolymer of fluorinated oxazoline combined with either 2-methyl- or 2-ethyl-2-oxazoline, her invention enhances the usability of polyurethanes in critical medical contexts.
Career Highlights
Lisa C. Grimminger currently works at E.I. DuPont de Nemours and Company, a leading organization in materials science. Her role involves research and development aimed at improving the performance and safety of materials used in medical applications. Grimminger's expertise in biocompatible materials positions her as a key figure in advancing innovative technologies in healthcare.
Collaborations
Throughout her career, Grimminger has collaborated with esteemed colleagues such as Sharon Loretta Haynie and Mureo Kaku. These partnerships have fostered a creative environment conducive to innovation, allowing them to explore and develop new ideas in material science.
Conclusion
Lisa C. Grimminger’s contributions to the field of biocompatible materials exemplify the impact that focused research and innovation can have on real-world applications. With her inventive spirit and dedication to improving medical technologies, she continues to pave the way for advancements in healthcare, significantly shaping the future of biocompatible options in medical devices.
